Restenosis

Peripheral Stent Implants Market to Close in on US$ 6 Bn by 2030, Driven by Increasing Peripheral Artery Disease Patient Pool Worldwide - Persistence Market Research

Retrieved on: 
Tuesday, January 12, 2021
Interventional radiology, Medical specialties, Medical devices, Medicine, Medical technology, Interventional cardiology, Stent, Steroid eluting sinus stent, Drug-eluting stent, Restenosis

Further, rising adoption of vascular stenting procedures is also surging demand for peripheral stents, propelling the growth of the global peripheral stent implants market.

Key Points: 
  • Further, rising adoption of vascular stenting procedures is also surging demand for peripheral stents, propelling the growth of the global peripheral stent implants market.
  • The global peripheral stent implants market is expected to exhibit a healthy CAGR of nearly 7% over the forecast period (20202030).
  • Higher peripheral artery disease patient pool and increasing adoption of peripheral vascular stents in Asian countries are expected to propel market growth in the region.
  • Get Full Access of Report: https://www.persistencemarketresearch.com/checkout/32225
    Manufactures in the peripheral stent implants market are actively focusing on launching new products to hold a better position in the peripheral stent implants market.

Global PTA Balloon Catheters Device Pipeline Assessment Report 2020 - Focus on Standard Balloon Catheters and PTA Peripheral DEB Catheters - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 31, 2020
Medical devices, Health, Medical specialties, Medicine, Clinical medicine, Angioplasty, Interventional radiology, Restenosis, Catheter, Percutaneous, Balloon catheter, Cordis

The "PTA Balloon Catheters - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PTA Balloon Catheters - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.
  • "PTA Balloon Catheters-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the PTA Balloon Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • PTA Balloon Catheters segment includes Standard Balloon Catheters and PTA Peripheral DEB Catheters.
  • A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis, or restenosis of the peripheral arteries.

Global Drug-Eluting Stents Market (2020 to 2024) - Featuring Abbott, Biosensors International & Cook Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, November 16, 2020
Medical devices, Health, Interventional cardiology, Medical specialties, Medicine, Clinical medicine, Medical devices, Drug-eluting stent, Cardiology, Stent, Restenosis, Coronary stent, Bare-metal stent, Percutaneous coronary intervention

There has been remarkable growth in the development of coronary stents to avoid restenosis and thrombosis.

Key Points: 
  • There has been remarkable growth in the development of coronary stents to avoid restenosis and thrombosis.
  • Improvements include progress in the design and conformation of metallic or resorbable structures, with an adequate balance between trackability and radial force.
  • These developments led to growth in the drug-eluting stent market over the forecast period.
  • These phenomena are anticipated to fuel drug-eluting stents market growth over the forecast period.

Groundbreaking Endovascular Clinical Trial Results Announced at VIVA20

Retrieved on: 
Friday, November 6, 2020
Medical specialties, Medicine, Health, Cardiology, Restenosis, Surgery, Interventional radiology, Medical devices, Stent, Stenosis, Clinical trial

SAN JOSE, Calif., Nov. 6, 2020 /PRNewswire/ --VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the first five of ten highly anticipated late-breaking clinical trial results presented at the VIVA20 virtual meeting.

Key Points: 
  • SAN JOSE, Calif., Nov. 6, 2020 /PRNewswire/ --VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the first five of ten highly anticipated late-breaking clinical trial results presented at the VIVA20 virtual meeting.
  • Below are highlights of this afternoon's late-breaking clinical trial presentations:
    This IN.PACT Global Study is the first presentation of 5-year data from a real-world, drug-coated balloon (DCB) global study.
  • The mean lesion length in this clinical cohort was 12.10 9.54cm, with 18.0% in-stent restenosis, 35.5% total occlusions, and 68.7% calcification.
  • Since the results of this real-world study were first published, safety and effectiveness through 5 years have been sustained.

InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study

Retrieved on: 
Thursday, September 3, 2020
Cardiology, Medicine, Health care, Health, Restenosis, Surgery, Interventional radiology, Medical devices, ESC Congress, Stent

In the study, 354/480 patients completed the 12-month follow-up with only 1 patient experiencing in-stent restenosis, 0.28% (1/354).

Key Points: 
  • In the study, 354/480 patients completed the 12-month follow-up with only 1 patient experiencing in-stent restenosis, 0.28% (1/354).
  • Finally, 46/480 patients completed the 60-month follow-up period with one more case of in-stent restenosis and no additional cases of device-related stroke.
  • The ESC Congress 2020 is being held digitally from August 29-September 2, 2020 and can be accessed via https://www.escardio.org/Congresses-&-Events/ESC-Congress.
  • The study is an all-comer, all-referrals-tracked study with no exclusion criteria other than a lack of Neurovascular Team-determined indication.

2020 Market Study on the Future of Therapy: Technology Advances in Drug-device Combination Products - ResearchAndMarkets.com

Retrieved on: 
Monday, August 10, 2020
Pharmaceutical, Health, Medical devices, Medical specialties, Medicine, Interventional cardiology, Clinical medicine, Medical devices, Cardiology, Interventional radiology, Stent, Restenosis, Coronary stent, Drug-eluting stent, Percutaneous coronary intervention

3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity

Key Points: 
  • 3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity
    4.2 Future of Coronary Stents: Gene Eluting Stents to Overcome Restenosis and Late-stent Thrombosis Challenges
    4.6 Business Growth Opportunities - Patient Centric, Patient Specific, and Cost-effective Imaging Redefining Future of Therapy
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005426/en/

Global Restenosis Pipeline Research Monitor, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Restenosis, Surgery, Drug pipeline, Pipeline

The "Restenosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Restenosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • The Restenosis pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • This Restenosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Restenosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Restenosis pipeline.

AngioSoma Focusing on Development of Coating for Metal Stents

Retrieved on: 
Wednesday, May 27, 2020
Medical specialties, Medicine, Clinical medicine, Neurosurgery, Vascular surgery, Cardiology, Medical devices, Interventional radiology, Carotid stenting, Restenosis, Stent, Carotid endarterectomy

Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.

Key Points: 
  • Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.
  • Our coating is a biodegradable, resorbable and hemocompatible surface substrate coating for metal stents to provide embolic protection in stenting procedures.
  • We believe our coating for stents has increased potential over and above what is on the market now to block restenosis (recurrence of narrowing).
  • We consider the addressable market for stents includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA19

Retrieved on: 
Tuesday, November 5, 2019
Medicine, Medical specialties, Cardiovascular system, Interventional radiology, Angioplasty, Femoral artery, Interventional cardiology, Percutaneous coronary intervention, Restenosis

Below are highlights of this morning's six late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's six late-breaking clinical trial presentations.
  • Mortality and freedom from TLR were evaluated for DES and percutaneous transluminal angioplasty (PTA)/bare-metal stent (BMS) risk factor groups.
  • The intent-to-treat mortality analysis comparing the DES primary randomization group to the PTA primary randomization group was not significant (P = .08).
  • SELUTION SFA is a prospective, controlled, multicenter, open-label, single-arm clinical trial treating superficial femoral artery (SFA) lesions (lesion length, 51.3 40.3 mm; 34% moderate-severe calcification).

Philips introduces new 200mm and 150mm Stellarex 0.035” low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients

Retrieved on: 
Tuesday, October 15, 2019
Medical specialties, Medicine, Circulatory system, RTT, Cardiology, Aging-associated diseases, Restenosis, Surgery, Peripheral artery disease, Interventional cardiology, Coronary artery disease, Artery disease

The new balloons broaden physicians treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis and expand the Stellarex portfolio, which has a proven significant treatment effect and high safety profile.

Key Points: 
  • The new balloons broaden physicians treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis and expand the Stellarex portfolio, which has a proven significant treatment effect and high safety profile.
  • The 200mm and 150mm Stellarex 0.035 low-dose DCBs are now available in the U.S. and will be rolled out to other markets in due course.
  • Broadening physicians treatment options helps ensure more PAD patients will receive treatment before the disease progresses.
  • Our integrated solutions advance minimally invasive procedures for patients with coronary artery disease, peripheral artery disease and lead extraction indications.